NCT06563804 2026-03-30
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier
Phase 1/2 Terminated
Clinical Trials
114 trialsNCT04347616 2026-03-16
NK4AML
Radboud University Medical Center
Phase 1/2 Terminated
NCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT04809467 2026-02-04
topMIND
Incyte Corporation
Phase 1/2 Terminated
NCT05787496 2026-01-28
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
Phase 1 Terminated
NCT04824794 2025-12-22
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Phase 1/2 Terminated
NCT04678336 2025-10-15
CD123 Redirected T Cells for AML in Pediatric Subjects
University of Pennsylvania
Phase 1 Terminated
NCT05961839 2025-09-22
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Schrödinger, Inc.
Phase 1 Terminated
NCT04951778 2025-08-27
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Celgene
Phase 1 Terminated
NCT02675452 2025-07-09
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Amgen
Phase 1 Terminated
NCT04789655 2025-05-31
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Celgene
Phase 1 Terminated
NCT04735575 2025-05-28
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 1/2 Terminated
NCT05038800 2025-05-21
MK-0482-002
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT03765541 2025-04-10
DEXAML-03
University Hospital, Toulouse
Phase 3 Terminated
NCT03038230 2025-04-06
MCLA-117 in Acute Myelogenous Leukemia
Merus B.V.
Phase 1 Terminated
NCT04477291 2025-03-07
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Aptose Biosciences Inc.
Phase 1 Terminated
NCT04342962 2025-01-30
Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Terminated
NCT01743807 2025-01-27
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT04887259 2025-01-27
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
Lava Therapeutics
Phase 1 Terminated
NCT03755154 2024-10-16
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Servier
Phase 1 Terminated
NCT02353143 2024-08-12
ARMY
Menarini Group
Phase 1 Terminated
NCT05360238 2024-07-22
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
Mustang Bio
Phase 1/2 Terminated
NCT05645744 2024-07-22
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Mustang Bio
Terminated
NCT05720052 2024-07-18
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
MingSight Pharmaceuticals, Inc
Phase 1/2 Terminated
NCT02384954 2024-07-03
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Altor BioScience
Phase 1/2 Terminated
NCT04113616 2024-03-22
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Kartos Therapeutics, Inc.
Phase 1/2 Terminated
NCT04478695 2024-03-08
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
Amgen
Phase 1 Terminated
NCT02013167 2024-03-05
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Terminated
NCT05345938 2024-02-23
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Terminated
NCT01186328 2024-02-01
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT05107856 2024-01-31
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
Phase 1 Terminated
NCT04092179 2024-01-24
ENAVEN-AML
University Health Network, Toronto
Phase 1/2 Terminated
NCT03624036 2023-11-18
ZUMA-8
Gilead Sciences
Phase 1 Terminated
NCT03572634 2023-11-09
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT03969420 2023-11-09
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT02096042 2023-10-10
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02957032 2023-10-10
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Philogen S.p.A.
Phase 1 Terminated
NCT04214093 2023-08-02
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
AstraZeneca
Phase 1 Terminated
NCT05256277 2023-05-16
NK Cell Therapy for AML
Zhejiang University
Phase 1 Terminated
NCT04730349 2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT05247957 2023-01-13
NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Hangzhou Cheetah Cell Therapeutics Co., Ltd
Phase NA Terminated
NCT03484520 2022-12-30
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
Phase 1 Terminated
NCT03410407 2022-10-26
AML1617
Gruppo Italiano Malattie EMatologiche dell'Adulto
Terminated
NCT03218683 2022-09-23
Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.
AstraZeneca
Phase 1 Terminated
NCT02267863 2022-08-22
A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
Aptose Biosciences Inc.
Phase 1 Terminated
NCT02361346 2022-08-18
MT-3724NHL001
Molecular Templates, Inc.
Phase 1/2 Terminated
NCT03063203 2022-06-02
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Washington University School of Medicine
Phase 2 Terminated
NCT03552029 2022-05-20
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Terminated
NCT01158885 2021-10-26
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2 Terminated
NCT02319369 2021-10-11
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Daiichi Sankyo
Phase 1 Terminated